Skip to main content

Table 3 Brain imaging findings of older adults with depression and parkinsonian symptoms

From: Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series

Case No Structural brain MR imaging DaT scan*
  MTA-Scheltens Score** White matter lesions/Fazekas Score*** Specific Binding Index right Benamer’s criteria****
    Right Left Rater 1 Rater 2
1 2 1 2.17 2.10 0 0
2 1 2 2.05 2.12 1 1
3 1 0 2.04 2.03 0 0
4 No atrophy / Computerized tomography (CT) scan 2.03 2.02 0 1
5 2 1 2.02 2.06 0 0
6 No atrophy / Computerized tomography (CT) scan 2.00 1.88 2 3
7 2 1 1.85 2.07 1 1
8 2 Bilateral basal ganglia ischemic lesions/3 1.51 1.67 1 1
  1. * iofluropane iodine-123 (DAT) single-photon emission computed tomography imaging (SPECT)
  2. **Medial Temporal Lobe Atrophy (MTA) -Scheltens Score ranging from 0 (no atrophy) to 4 (severe atrophy)
  3. ***The 4-point Fazekas score is a whole brain scale: 0: No lesion or a single punctuate white matter lesion; 1: multiple punctuate lesions; 2: Beginning confluent lesions; 3: large confluent lesions
  4. **** Benamer’s criteria: 0: preserved and largely symmetrical striatal tracer uptake; 1: asymmetric uptake with normal or almost normal putamen activity in one hemisphere, and with a more marked reduction in the contralateral putamen; 2: significant bilateral reduction in putamen uptake with activity confined to the caudate nuclei; 3: virtually absent uptake bilaterally affecting both putamen and caudate nuclei